Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus GENCEPT 10 11 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus GENCEPT 10 11 28.
ENOVID-E vs GENCEPT 10/11-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive